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Background: Accurate interpretation of HIV drug resistance (HIVDR) testing is challenging, yet important for patient
care. We compared genotyping interpretation, based on the Stanford University HIV Drug Resistance Database
(Stanford HIVdb), and virtual phenotyping, based on the Janssen Diagnostics BVBA’s vircoTYPE™ HIV-1, and
investigated their level of agreement in antiretroviral (ARV) naive patients in Asia, where non-B subtypes
predominate.
Methods: Sequences from 1301 ARV-naive patients enrolled in the TREAT Asia Studies to Evaluate
Resistance – Monitoring Study (TASER-M) were analysed by both interpreting systems. Interpretations from both
Stanford HIVdb and vircoTYPE™ HIV-1 were initially grouped into 2 levels: susceptible and non-susceptible.
Discrepancy was defined as a discordant result between the susceptible and non-susceptible interpretations from
the two systems for the same ARV. Further analysis was performed when interpretations from both systems were
categorised into 3 levels: susceptible, intermediate and resistant; whereby discrepancies could be categorised as
major discrepancies and minor discrepancies. Major discrepancy was defined as having a susceptible result from
one system and resistant from the other. Minor discrepancy corresponded to having an intermediate interpretation
in one system, with a susceptible or resistant result in the other. The level of agreement was analysed using the
prevalence adjusted bias adjusted kappa (PABAK).
Results: Overall, the agreement was high, with each ARV being in “almost perfect agreement”, using Landis and
Koch’s categorisation. Highest discordance was observed for efavirenz (75/1301, 5.8%), all arising from susceptible
Stanford HIVdb versus non-susceptible vircoTYPE™ HIV-1 predictions. Protease Inhibitors had highest level of
concordance with PABAKs all above 0.99, followed by Nucleoside Reverse Transcriptase Inhibitors with PABAKs
above 0.97 and non-NRTIs with the lowest PABAK of 0.88. The 68/75 patients with discordant efavirenz results
harboured the V179D/E mutations compared to 7/1226 with no efavirenz discrepancy (p-value <0.001). In the
3-level comparison, all but one of the discrepancies was minor.
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Conclusions: The two systems agreed well with lowest concordance observed for efavirenz. When interpreting
HIVDR, especially in non-B subtypes, clinical correlation is crucial, in particular when efavirenz resistance is
interpreted based on V179D/E.
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In recent years, developing countries have experienced a
rapid expansion of antiretroviral drugs (ARVs) in the
treatment of HIV-1 infection [1]. Treatment-naive HIV-
infected patients may harbour drug-resistance-associated
mutations (RAMs) prior to their initial treatment
through infection from pre-treated patients. The preva-
lence of RAMs in treatment-naive patients in resource
limited settings was found to vary between different set-
tings [2-5], mainly below 10%. This implies that drug re-
sistance monitoring prior to treatment may aid the
selection of appropriate ARVs.
The aim of the Therapeutics, Research, Education and
AIDS Training in Asia (TREAT Asia) Studies to Evaluate
Resistance – Monitoring Study (TASER–M) is to monitor
HIV-1 drug resistance (HIVDR) and its effects in HIV-
infected patients in Asia. The TASER-M cohort consists
mainly of ARV-naive Asian individuals infected with HIV-
1 AE circulating recombinant form (CRF01_AE) [6]. This
is in contrast to developed countries where HIV-1 subtype
B predominates. HIV-1 subtypes differ in their gene
sequences and this may influence susceptibility to ARVs
[7,8]. Some non-B subtypes have natural polymorphisms
at resistance associated positions [9], leading to possible
misinterpretation of drug susceptibility.
There are several software-based drug resistance inter-
pretation systems currently available, which are used in
patient care to design subsequent regimens. The two
systems adopted in TASER-M are (i): the Stanford Uni-
versity HIV Drug Resistance Database (Stanford HIVdb)
which has a publicly available tool that provides geno-
typic analysis and interpretation via web-based sequence
submission. The Stanford HIVdb uses a rules based sys-
tem in which all mutation scores are added to derive a
level of predicted viral resistance to each ARV. These
rules are pre-determined based on research findings of
published studies [10,11]; (ii) Janssen Diagnostics BVBA’s
vircoTYPETM HIV-1 which is a proprietary software that
provides a predicted or ‘virtual’ phenotype of a se-
quence, based on a large genotype-phenotype database.
The tool provides a calculated fold change (FC) pre-
dicted phenotype of the patient’s genotype, compared
to a reference sequence, derived from linear regression
modelling [12,13]. The Stanford HIVdb and vircoTYPETM
HIV-1 utilise consensus B and HXB2, respectively, as the
reference strains [10,11,13,14].Because different interpretation algorithms use differ-
ent rules to predict drug susceptibility, results may dif-
fer. Studies have shown that differences do exist with
varying degree of discordances [15-21], and the propor-
tion of discordances for each ARV could be subtype
dependent [22,23].
The objective of this study was to determine the yet
unstudied level of agreement between genotype and virtual
phenotype from the Stanford HIVdb and vircoTYPETM
HIV-1 resistance interpretation in the TASER-M cohort,
where non-B subtypes predominate.
Methods
TASER-M recruitment began in 2007, with a total of 12
participating sites from Thailand, Hong Kong, Malaysia,
Philippines and Indonesia. The TASER-M cohort com-
prises of 95% treatment naive patients at time of enrol-
ment with pre-treatment sequences contributing to more
than 90% of total available sequences. Ethics approvals
were obtained from the University of New South Wales
Ethics Committee and institutional review boards at the
participating clinical sites. Informed consent was obtained
from participants prior to enrolment. ARV treatment-
naive patients were required to have viral load and resist-
ance testing performed prior to initiation of ARVs and at
yearly intervals post initiation [24]. Genotyping was per-
formed in local TAQAS [25] laboratories.
Sequences were included in this analysis if they were
pre-treatment sequences derived from HIV-infected
patients enrolled as treatment-naive in the TASER-M co-
hort. FASTA sequence files were analysed by both the
Stanford HIVdb and vircoTYPE™ HIV-1. FASTA files were
submitted to the Stanford HIVdb (Version 6.0.11) through
Sierra – The Stanford HIV Web Service (Version 1.0) for
genotypic interpretation. Subtyping was analysed using
REGA HIV-1 Subtyping Tool - Version 2.0.
For virtual phenotyping, FASTA files were submitted to
Janssen Diagnostics. The vircoTYPETM HIV-1 (VPT 4.3.01)
results were then transferred to Advanced Biological La-
boratories (ABL) TherapyEdge 3.9.2 web based software,
and retrieved directly from TherapyEdge 3.9.2. The inter-
pretation of the FC is made in reference to the clinical
cut-offs (CCOs) or biological cut-offs (BCOs) [26,27]. If
the CCOs are used, the resistance interpretations are cate-
gorised as maximal response if the FC is less than the
lower CCO (CCO1), reduced response if the FC is
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response if the FC is greater than CCO2. For ARVs utilis-
ing the BCO, the interpretations are either susceptible if
the FC is below the BCO, or resistant if the FC is above
the BCO [14]. For lamivudine and etravirine, a combin-
ation of both BCO and CCO are used in vircoTYPETM
HIV-1 predictions. The lower CCO (CCO1) is replaced by
the BCO, resulting in two cut-off points: BCO and CCO2.
If the FC value is below the BCO, the interpretation will
be susceptible. If the FC is between the BCO and CCO2,
the result will be classified as reduced response, whilst
minimal response is the resulting interpretation when FC
is greater than CCO2 for these three drugs.Two level interpretations
A total of 15 ARV interpretations (7 Nucleoside Reverse
Transcriptase Inhibitors (NRTIs), 3 non-NRTIs (NNRTIs)
and 5 Protease Inhibitors (PIs)) and were compared. The
Stanford HIVdb provides 5 levels of susceptibility prediction
for each ARV (susceptible, potential low-level resistance,
low-level resistance, intermediate resistance and high-level
resistance). The vircoTYPETM HIV-1 utilises either 2 or 3-
level resistance prediction for any given ARV, depending
on the cut-offs used.
To be able to compare both systems effectively, the 5-
level interpretations from the Stanford HIVdb needed to
be combined in order to match the levels of interpretation
provided by vircoTYPETM HIV-1. For comparison of all
ARVs, 2-level comparisons were performed to enable the
inclusion of ARVs where virtual phenotyping only pro-
vided predictions at 2 levels. That is, the 3-level interpre-
tations available from the Stanford’s Sierra database
(susceptible, intermediate and resistant), initially grouped
from the 5-level interpretation, were combined further
into susceptible (susceptible) and non-susceptible (inter-
mediate and resistant). The vircoTYPETM HIV-1’s suscep-
tible and maximal response were categorised as
susceptible whilst reduced response, minimal response
and resistant were grouped as non-susceptible. Discrep-
ancy was defined as a discordant drug resistant interpret-
ation between the Stanford HIVdb and the vircoTYPETM
HIV-1 report, using the 2-level interpretations, i.e. sus-
ceptible versus non-susceptible, and vice versa.
The ARV that exhibited the highest discordances was
chosen for further investigation into the mutation pat-
tern and predicted FC values associated with the dis-
crepancies. The mutations were analysed using the
Stanford’s HIV Drug Resistance Mutations by Drug
Class (November 6, 2009) [28] (Stanford HIVDR list)
only, as vircoTYPETM HIV-1’s list of relevant mutations
was not available. Differences in FC values were ana-
lysed by comparing the median FC between the dis-
cordant and non-discordant groups.Three level interpretations
To evaluate whether the discrepancies were major or
minor in nature, a sub comparison was also made using
3-level susceptibility predictions. In this comparison
however, efavirenz, nevirapine and emtricitabine were
excluded as they did not have 3 levels of virtual pheno-
type interpretations available. As a consequence, the
available prediction output for all other ARVs were sus-
ceptible, maximal response, reduced response and min-
imal response. The susceptible category here belongs to
lamivudine and etravirine as a result of the BCO being
used as the lower cut off point, instead of the CCO1,
thus replacing “maximal response” with “susceptible” in-
terpretation. The vircoTYPETM HIV-1’s susceptible and
maximal response were then categorised as susceptible,
while reduced response was intermediate, and minimal
response was defined as resistant. The interpretations
were then compared to the 3-level Stanford HIVdb
results. Major discrepancy was defined as having a sus-
ceptible result from one system and resistant from the
other. Minor discrepancy corresponded to having an
intermediate interpretation in one system, with a sus-
ceptible or resistant result in the other.Statistical analysis
To take into account agreement due to chance, the
prevalence adjusted bias adjusted kappa coefficient
(PABAK) was used to analyse the level of agreement
between the two interpretation systems [29]. The inter-
pretation of PABAK was made based on Landis and
Koch’s [30] categorisation: 0 to 0.20 slight agreement; 0.21
to 0.40 fair agreement; 0.41 to 0.60 moderate agreement;
0.61 to 0.80 substantial agreement; and 0.81 to 1.00 almost
perfect agreement.
Median values were analysed using Wilcoxon rank
sum test. Categorical data was analysed using Chi-
square, Fisher’s exact test or McNemar’s test.
Analyses were performed using SAS software version
9.2 (SAS Institute Inc., Cary, NC, USA) and STATA soft-
ware version 10.1 (STATA Corp., College Station, TX,
USA). Ordinal scale PABAK (PABAK-OS) for 3-level in-
terpretation was analysed using PABAK-OS web-based
tool [31].Results
Demographics
A total of 1301 eligible naive patients consented between
2007 and September 2010 were included. Out of the 1301
baseline sequence files analysed, most were from male
patients (66%) with a median age of 36 years (IQR 31–44).
The main ethnicity was Thai (71%) followed by Chinese
(20%). Heterosexual contact was the predominant mode
of exposure (72%). The median pre-treatment CD4 and
Table 1 PABAK values for each ARV – 2-level interpretation
Drug
class
Drug Proportion
observed
agreement
PABAK 95%CI of
PABAK
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copies/mL (IQR 41,345 – 230,000), respectively. The main
subtype was CRF01_AE (78%). Subtype B accounted for
15% and other non-B subtypes were 7%.NNRTI Efavirenz 0.94 0.88 (0.86 - 0.91)
Etravirine 0.99 0.97 (0.96 - 0.99)
Nevirapine 0.99 0.98 (0.97 - 0.99)
NRTI Abacavir 0.99 0.97 (0.96 - 0.99)
Didanosine 0.99 0.97 (0.96 - 0.99)
Emtricitabine 1.00 1.00 (1.00 -1.00)
Lamivudine 1.00 1.00 (1.00 -1.00)
Stavudine 0.99 0.98 (0.97 - 0.99)
Tenofovir 1.00 0.99 (0.99 - 1.00)
Zidovudine 0.98 0.97 (0.95 - 0.98)
PI Atazanavir/r 1.00 0.99 (0.99 - 1.00)
Darunavir/r 1.00 1.00 (1.00 - 1.00)
Lopinavir/r 1.00 1.00 (0.99 - 1.00)
Saquinavir/r 1.00 1.00 (0.99 - 1.00)
Tipranavir/r 1.00 1.00 (0.99 - 1.00)Two level interpretations
The number of discrepant results, using the 2-level in-
terpretation method, between Stanford HIVdb and the
vircoTYPE™ HIV-1 for each ARV are illustrated in Figure 1.
The number of discrepancies ranged from 0 to 75. The
ARV with the highest number of discordances was efavirenz
(75/1301, 5.8%), followed by zidovudine (21/1301, 1.6%)
and etravirine and abacavir (18/1301, 1.4% each). All of
the 75 discrepancies for efavirenz arose from susceptible
interpretation from the Stanford HIVdb versus non-
susceptible interpretation from vircoTYPETM HIV-1. The
observed efavirenz agreement was 94% with 1199
patients being susceptible and 27 non-susceptible. For zi-
dovudine, the observed agreement was 98% with 1274
susceptible and 6 non susceptible patients. Emtricitabine
and darunavir/r both had 100% agreement with no dis-
crepancy, however 1293/1301 agreements for emtricita-
bine were from susceptible prediction and 8/1301 were
non-susceptible. For darunavir/r, 100% of the agreements
were susceptible from both systems.
The PABAK values (Table 1) ranged from 0.88 to 1.00.
The lowest PABAK (0.88) was observed for efavirenz. This
is consistent with efavirenz having the lowest number of
concordances. The PABAK for etravirine, abacavir,Figure 1 Number and percentage of discordant drug resistance interdidanosine and zidovudine was second lowest at 0.97. For
the two drugs with no discrepancy, the corresponding
PABAK for both drugs was 1.00 with 95% confidence
interval (95%CI) of (1.00-1.00). Overall, PIs had highest
level of concordance with individual PABAK values all
above 0.99, followed by NRTIs with PABAKs above 0.97
and NNRTIs with lowest PABAK of 0.88. Using Landispretations for each ARV – 2-level interpretation.
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interpreting systems for all ARVs considered could be
classified as “almost perfect agreement” since the PABAK
values all lie within the 0.81-1.00 interval.
As efavirenz had significantly higher number of discor-
dances compared to other ARVs (p-value<0.001 for all
comparisons) and the lowest PABAK, it was chosen for fur-
ther investigation. The relevant mutations were extracted
from the Stanford HIVdb and compared against the Stan-
ford HIVDR list only. 68/75 (91%) patients with discrepant
efavirenz results harboured the V179D/E mutations
(V179D (83%), V179E (17%)) compared to only 7/1226
(0.6%) of patients with no efavirenz discrepancy (p-value
<0.001). Apart from V179D/E, these 68 patients did not
present any other efavirenz RAMs. The other 7/75 (9%)
patients who had the discrepancy did not harbour any
efavirenz-associated mutations. These 7 discrepant patients
may harbour other RAMs that were found to significantly
affect susceptibility to efavirenz by the vircoTYPETM HIV-
1’s algorithm, which were not present in the Stanford
HIVDR list. Of note, T39K, K43S, K122E, D123S, D177E,
Q207A and R211S were the most common RT-mutations
(86%) found in these 7 patients with respect to the refer-
ence wildtype virus. However no common RT-mutation
was identified across all 7 patients. Out of the 75 patients
with efavirenz discrepancy, 79% were non-B subtype com-
pared to 85% in patients showing concordance (p=0.135).
Among the 1226 patients with no discrepancy, the
efavirenz-associated mutations were A98G (0.3%), K103N
(0.8%), K103S (0.2%), V106M (0.2%), V179D (0.6%),
Y181C (0.6%), G190A (0.3%), G190E (0.1%), P225H
(0.2%), F227C (0.1%) and K238T (0.1%). RAMs found in
discrepant patients for other NNRTIs were: etravirine (18
discordances): V179D (38.9%), V179E (11.1%), G190A
(5.6%) and G190E (5.6%); nevirapine (12 discordances)
V179D (75%); V179E (8.3%) and F227C (8.3%). Although
G190A/E and F227 were found in a proportion of these
patients, a similar pattern to efavirenz could be seen
whereby discrepant patients with V179D/E did not
harbour any additional NNRTI RAMs.
In vircoTYPETM HIV-1, the BCO was used to deter-
mine the level of susceptibility of efavirenz. Therefore
only one cut-off point (BCO = 3.3) and two interpreta-
tions were available. There was no discrepancy found in
patients with FC less than the assigned BCO of 3.3 for
efavirenz. That is, all patients with the discrepancies had
reported FC greater than 3.3, which resulted in a non-
susceptible or resistant virtual phenotype interpretation.
In light of 100% efavirenz discrepant patients possessing
non-susceptible virtual phenotype results, median FC
values were compared between the discordant and con-
cordant group for those with non-susceptible vircoTYPETM
HIV-1 interpretation only. This is because by restricting
the comparison to those that resulted in non-susceptibleinterpretation (FC>3.3), it was possible to make direct
comparison without diluting the results with the low FC
values whereby no discrepancy was found. There was a
total of 102 patients with FC above the BCO of 3.3 for efa-
virenz. Out of these 102 patients, 27 had no discrepant re-
sult, with median FC of 31.90 and inter quartile range
(IQR) (7.10-87.10). The median FC for those with discrep-
ancies was 5.10 (p-value <0.001; IQR 4.30-6.10). This sug-
gests that for patients with non-susceptible virtual
phenotype results for efavirenz, the group with the discor-
dances had a median FC that is lower and nearer to the
cut-off point than those without discordances.
Three level interpretations
Interpretations were regrouped into susceptible, inter-
mediate and resistant in order to determine the number
of minor and major discrepancies. Efavirenz, emtricita-
bine and nevirapine were excluded. Figure 2 and Table 2
indicate that all of the discordances, but one, were clas-
sified as minor discrepancies. The proportion of exact
agreement ranged from 98% to 100%. As with the two
level interpretations, darunavir/r had 100% agreement
with no discrepancy.
The results of Table 2 suggest that almost all of the
discrepancies that exist between Stanford HIVdb and
vircoTYPETM HIV-1 were minor in nature. That is, one
system produced an intermediate interpretation while
the other produced either a susceptible or resistant in-
terpretation. Etravirine was the only ARV that pos-
sessed a major discrepancy where the Stanford HIVdb’s
interpretation was susceptible and vircoTYPETM HIV-1
was resistant. Without the inclusion of efavirenz, the
number of minor discrepancies in Table 2 ranged
from 0 to 21. By comparing the 2 and 3-level discrep-
ancies, it was found that the total number of discrep-
ancies from the 3-level comparison was slightly
greater than that from the 2-level comparison for a
number of ARVs. For example, abacavir had 20 and 18
discrepancies in the 3 and 2-level comparisons, re-
spectively. This is due to the fact that the differences
between intermediate and resistant interpretations
would not have been captured in the 2-level categorisa-
tion, as both interpretations were grouped as non-
susceptible. However, the total discrepancies for
each ARV between the 2 and 3-level groupings dif-
fered by a maximum of 2, and the PABAK and
PABAK-OS agreement interpretations remained un-
changed, therefore the simplification of the interpre-
tations into two categories did not greatly alter the
discordance outcome.Discussion
The overall results suggest that both the Stanford HIVdb
and the vircoTYPETM HIV-1 provide comparable drug
Figure 2 Number and percentage of major and minor discrepancies for each ARV– 3-level interpretation, excluding efavirenz,
nevirapine and emtricitabine.
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virenz showed the highest number of disagreements, all of
which were Stanford HIVdb susceptible - vircoTYPETM
HIV-1 resistant pairs. The PABAK values for all ARVs
considered remained in the “almost perfect agreement”
category. The results from the 2-level comparison suggest
that the lowest level of agreement belongs to the NNRTI
drug class. This is in contrast to previous studies [15-19]
where NRTIs were found to have lowest concordances. Of
note, the majority of the patients in this cohort har-
boured CRF01_AE subtype virus, whereas B subtype was
predominant in preceding studies [16,17,19]. Studies
comparing non-B sequences reported highest discor-
dances in either PI or NRTI drug class [20,21].
The RAMs associated with efavirenz discrepancy were
V179D/E. These are likely to be natural polymorphismsTable 2 PABAK – OS – 3-level interpretation
Drug Class Drug Proportion observed
agreement
Minor discrep
NNRTI Etravirine 0.99 18
NRTI Abacavir 0.98 20
Didanosine 0.99 19
Lamivudine 1.00 1
Stavudine 0.99 16
Tenofovir 1.00 5
Zidovudine 0.98 21
PI Atazanavir/r 1.00 5
Darunavir/r 1.00 0
Lopinavir/r 1.00 2
Saquinavir/r 1.00 2
Tipranavir/r 1.00 4in HIV-1 RT. V179D/E are often found in treatment-
naive individuals infected with non-B subtypes [6,32,33].
V179D is associated with low-level resistance to NNRTIs
and is considered to have no significant effect on the ef-
ficacy of NNRTI–containing regimen. The 5-level Stan-
ford HIVdb predicted “potential low-level resistance” in
all sequences with discordant efavirenz interpretation
containing V179D/E. A combination of V106I and
V179D has been shown to confer significant resistance
to efavirenz [34]. Among TASER-M patients, only 1 had
a combination of V106I and V179D. V179D also confers
significant resistance to NNRTIs when presented together
with K103R [35]. Only 2 patients had a combination of
K103R and V179D.
Since the mutations were extracted and compared against
the Stanford HIVDR list only, it should be noted that theancy Major discrepancy PABAK-OS 95%CI of PABAK-OS
1 0.98 (0.96 - 1.01)
0 0.98 (0.96 - 1.01)
0 0.98 (0.96 - 1.01)
0 1.00 (0.97 - 1.03)
0 0.99 (0.96 - 1.01)
0 1.00 (0.97 - 1.02)
0 0.98 (0.95 - 1.01)
0 1.00 (0.97 - 1.02)
0 1.00 (0.97 - 1.03)
0 1.00 (0.97 - 1.03)
0 1.00 (0.97 - 1.03)
0 1.00 (0.97 - 1.02)
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those based on the Stanford HIVDR list alone. This is one
limitation of the study. The likely presence of additional
mutations in vircoTYPETM HIV-1 coupled with the differ-
ences in mutation weights or scores are the most likely
causes of the discrepancies. Therefore, the significance of
V179D/E found in this study should not be interpreted as
the cause of the differences between the two interpreting
systems, but merely reflects the mutation pattern based on
the Stanford HIVDR list. However, it has been reported
that natural polymorphisms found in non-B subtype have
contributed to the majority of the discordances, although
this was mainly associated with the protease region of the
sequence [20].
The 3-level comparison showed that most of the dis-
crepancies found were minor in nature. These may have
less clinical importance than the major discordances. The
availability of only two virtual phenotype predictions for
efavirenz, nevirapine and emtricitabine, another limitation
of this study, did now allow for further break down of dis-
cordant groups. As such, discrepancies between inter-
mediate and resistant categorisation for these three drugs
could not be captured. Nevertheless, the minor discrepan-
cies illustrated in this study suggest that the results did
not differ greatly from one system to the other.
The differences in median FC between those with and
without efavirenz discrepancies suggest that one should
take into consideration the actual predicted FC values in
addition to the resistance interpretation when evaluating
efavirenz resistance. Although discrepancies only oc-
curred in sequences with resistant interpretation, those
who were resistant with lower FC tended to result in
discordant interpretation compared to those with high
FC. Additionally, by simplifying resistance calls into
categories, the true value of predicted phenotype is
diminished. In the Stanford HIVdb, the 3 or 5-level
classification should also be interpreted together with
the resistance scores in order to take into account the
variation of susceptibility within each classification. It
would be of interest to re investigate when the CCOs
become available for efavirenz, nevirapine and emtri-
citabine. It is likely that the FC values associated
with efavirenz discrepancies would lie in the middle
region between CCO1 and CCO2, resulting in minor
discrepancies.Conclusions
This study has shown high concordance between the
Stanford HIVdb and vircoTYPETM HIV-1 in naive
patients. The differences in the proportions of discor-
dances from different patient groups reported in previous
studies [20,22,23] and the higher efavirenz discrepancies
compared to all other ARVs analysed indicate that moredata is required to enable the algorithms to adapt appro-
priately to different sequence variations. When interpret-
ing HIVDR, especially in non-B subtypes, careful
mutation-specific, interpretation of genotyping and vir-
tual phenotyping results are recommended to identify po-
tential discordances.
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